Kamada Ltd. Q2 2025 Earnings Recap

KMDA Q2 2025 August 13, 2025

Get alerts when KMDA reports next quarter

Kamada Limited reported strong second-quarter results, with total revenues increasing by 5% year-over-year, driven by a diverse product portfolio and effective cost management. The company raised its adjusted EBITDA guidance, reflecting robust growth prospects.

Earnings Per Share Beat

$0.13 vs $0.09 est.

+44.4% surprise

Revenue Miss

44754000 vs 155048170 est.

-71.1% surprise

Market Reaction

1-Day -1.08%

5-Day -5.56%

30-Day -7.45%

See KMDA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 2025 revenue reached $44.8 million, while first-half revenue totaled $88.8 million, marking an 11% year-over-year increase.
Adjusted EBITDA rose 20% year-over-year to $10.9 million in Q2, representing a 25% margin.
The company is expanding its biosimilar pipeline and anticipates notable revenue contributions from new products in the next 5 years.
FDA approval of a new plasma collection center in Houston boosts capacity, projected to generate $8-10 million annually at full utilization.
Kamada is actively pursuing business development and M&A opportunities to enhance its product portfolio and drive future growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KMDA on AllInvestView.

Next Q3 2025